Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.
Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...
This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...
Oprah Winfrey says taking weight-loss medications like Ozempic and Wegovy challenged and helped her understand the truth ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.
The skyrocketing popularity of weight-loss drugs like Wegovy, one of a class of drugs called GLP-1s, is fast becoming a state ...
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback